LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

DiaSorin Enters Indian IVD Market

By LabMedica International staff writers
Posted on 01 Aug 2012
Print article
DiaSorin (Saluggia, Italy) continues its expansion plan in Asia through the establishment of a Joint Venture Company (JV) with local partner Trivitron Healthcare (Chennai, India), an Indian medical technology company focused on manufacturing and distribution, with solutions in the in vitro diagnostics business.

DiaSorin has signed a joint venture (JV) with Trivitron Healthcare to enter India's EUR 400 million IVD market. Financial terms were not available.

In accordance with the JV Agreement, DiaSorin Group and Trivitron Group formed the limited liability company dubbed DiaSorin Trivitron Healthcare Private Ltd., headquarted in Chennai, in which the companies have 51% and 49% share respectively. It will directly operate in the Indian diagnostics market.

Device and diagnostics companies have known for some time that they can make better progress in India, which is the world's second fastest growing IVD market after China, by joining forces with a local partner.

Carlo Rosa, CEO of DiaSorin Group, commented, "The JV agreement with Trivitron is really important for the success of DiaSorin Group in a such relevant market as India, and represents an important pillar of the current and future expansion strategy of DiaSorin Group in Asia Pacific. [….] By combining the quality of DiaSorin systems and tests to Trivitron’s extensive knowledge of the Indian market, I’m confident that India will represent another important leg of revenues for us in the Asian region."

DiaSorin is active internationally in the market for in vitro diagnostics and immunodiagnostics. It develops, on an ongoing basis, a vast and innovative line of products that are used in analysis laboratories at universities, hospitals, and private testing facilities.

Trivitron is a global medical technology company of Indian origin focused on manufacturing, innovation, and distribution. The key focus segments include cardiology & implantable devices, imaging sciences (IVD), diagnostics, critical life support solutions (CLSS), and ophthalmology and dental technologies.

Related Links:

DiaSorin
Trivitron Healthcare


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more